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Abstract 
Skeletal muscle wasting is a consequence of numerous physiological conditions, 
including denervation, corticosteroid treatment, immobilization, and aging. The E3 
ubiquitin ligases, MuRF1 and MAFbx, are induced under nearly all atrophy conditions 
and are believed to play a key role in protein degradation in atrophying muscle. However, 
the preliminary data described in this study provides new evidence that MuRF1 may also 
act as a transcriptional modulator of atrophy-induced gene activity, including the 
regulation of MAFbx and MuRF1 expression. To characterize the transcriptional 
regulation of MuRF1 and MAFbx, reporter gene constructs containing fragments of the 
proximal promoter regions of these genes were developed, transfected into C2C12 cells 
with or without a MuRF1 expression plasmid and monitored for differences in reporter 
gene activity. The MuRF1 and MAFbx reporters each showed repressed activity in cells 
ectopically expressing MuRF1 compared to cells that did not overexpress MuRF1. 
Furthermore, ectopic expression of the myogenic regulatory factors (MRFs), MyoD1 and 
myogenin, caused significant activation of the MuRF1 and MAFbx reporter constructs. 
However, co-overexpression of MuRF1 with MyoD1 or myogenin resulted in reversal of 
MRF induction of reporter gene activity, and synergistic repression of a constructed E-
box reporter system. To further characterize the role of the MuRF1 gene product in 
repression of MuRF1 expression, a MuRF1 RING domain mutant and a MuRF1 c-
terminal mutant were created. The mutant constructs were then co-transfected along with 
MRF expression plasmids and the MuRF1 reporter construct into C2C12 cells and reporter 
gene activity was assessed. The MuRF1 RING mutant failed to reverse MRF activation 
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of the reporter gene, while the c-terminal mutant successfully reversed activation of the 
reporter gene.  These findings suggest that ubiquitin ligase activity is required for MuRF1 
transcriptional regulatory effects. These data offer exciting evidence of a potential new 
function for MuRF1 as a transcriptional modulator of atrophy-induced changes in gene 
expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 1: Overview of the Role of MuRF1 in Skeletal Muscle Atrophy 
 
Introduction  
 The goal of this thesis was to provide a better understanding of the transcriptional 
regulation of atrophy-induced genes, called atrogenes. Atrogenes are genes commonly 
regulated under models of skeletal muscle atrophy, which is caused by a number of 
physiological conditions including chronic disease, denervation, immobilization, and 
aging.1, 2 Key components of the atrophy pathways have been identified; however, the 
role and regulation of these components are not yet fully understood. The Muscle RING 
(Really Interesting New Gene) Finger Protein-1 (MuRF1) gene has been identified as a 
major effector of skeletal muscle wasting.1 MuRF1 has been classified as an E3-ubiquitin 
ligase that tags proteins for destruction by the proteasome.3 MuRF1 is also 
transcriptionally up-regulated under virtually all atrophy conditions; however the 
mechanism of its regulation is currently incomplete.1 Therefore, the goal of this research 
was to further explore the mechanisms by which MuRF1 is transcriptionally regulated 
and expand on the role of MuRF1 in the skeletal muscle atrophy signature. 
 The primary objective of this investigation was to further characterize the 
transcriptional regulation of MuRF1, as well as its potential downstream effects, 
including the possibility that MuRF1 coordinates a negative feedback mechanism to 
transcriptionally down-regulate a subset of atrophy-induced genes, including itself, and a 
second E3-ubiquitin ligase, Muscle Atrophy F-box (MAFbx). The data presented herein 
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demonstrates that the mechanism by which MuRF1 transcriptionally regulates a diverse 
array of atrogenes is mediated by direct and/or indirect interaction and modification of 
muscle-specific transcription factors, including myogenin and MyoD1. MyoD1 and 
myogenin sequentially and transiently associate with the promoters of a wide array of 
muscle-specific genes, and are necessary for the development of functional skeletal 
muscle and myogenic commitment, respectively.4, 5 MuRF1 and MAFbx expression rise 
dramatically during most models of atrophy,1 as does the expression of MyoD1 and 
myogenin.6 Furthermore, MyoD1 and myogenin have been shown to be important 
regulators of neurogenic atrophy-induced gene expression (i.e. denervation), including 
the induction of MuRF1 and MAFbx.6 Our work focused on the cooperative 
transcriptional regulation of atrogenes through the interaction of MuRF1 and myogenic 
regulatory factors (MRFs), such as MyoD1 and myogenin. Furthermore, the importance 
of specific domains of the MuRF1 protein in atrogene regulation was also explored. 
Specifically, the role of the RING finger domain and the acidic carboxyl-terminal domain 
of the MuRF1 protein in modulating MRF activity were investigated.  
 
MuRF1 as an E3 Ligase In the Ubiquitin-Proteasome Pathway 
 The findings from this project reveal a potentially new functional role for MuRF1 
in the skeletal muscle atrophy cascade. MuRF1 has long been known to be involved in 
mediation of muscle atrophy, presumably by targeting proteins for degradation via the 
well-characterized ubiquitin-proteasome system (UPS), which is the main mechanism for 
degradation of intracellular proteins.7 Briefly, proteins are first marked by the covalent 
addition of ubiquitin, a 76 amino acid polypeptide. These tagged proteins are then 
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degraded into smaller peptides through proteolysis by the 26S proteasome complex 
(Figure 1).  
 
 
Figure 1. Schematic diagram of the ubiquitin-proteasome system.8  
 
  The mechanism by which proteins are tagged with ubiquitin involves a three step 
process. The E1 ubiquitin-activating proteins first establish a form of ubiquitin (Ub) 
which is highly reactive.9 After activation, the ubiquitin is forwarded from an E1 to 
ubiquitin carriers known as E2 proteins.9 E2 proteins typically exhibit a conserved core 
region of 16kDa.10 This region contains cysteine, which is used in the thiol-ester linkage 
between the activated ubiquitin and the enzyme.10 The main function of these E2 enzymes 
is to serve as ubiquitin couriers for E3 ubiquitin-protein ligases, such as MuRF1. The E3 
ubiquitin ligases transfer the activated ubiquitin to a lysine residue on the final protein 
substrate, typically forming long ubiquitin chains which are then recognized by the 26S 
proteasome. It is likely that it is the E3 ligase which is responsible for the discrimination 
and accuracy of the process of ubiquination.11 The resulting ubiquitin-tagged protein 
  
4 | P a g e  
 
complex is then broken down into small peptides by the proteolytic activity of the 26S 
proteasome.12 In skeletal muscle, this breakdown of protein may contribute to loss of 
muscle mass. MuRF1, which has been classified as an E3 ubiquitin ligase, has been well 
characterized as a general marker of skeletal muscle wasting.1 
 
MuRF1 as a Marker of Skeletal Muscle Atrophy 
 MuRF1 expression has previously been shown to be induced under different 
atrophy conditions.1 This work measured changes in mRNA levels over time in 
experimental subject mice following atrophy-inducing conditions, including denervation 
of the sciatic nerve, immobilization of the hind limbs, and hind-limb suspension.1 
Following transcript profiling, Northern blots were used to verify the expression patterns 
of potential genes of interest (Figure 2).1 While many genes showed increased expression 
under one or two conditions, only two genes showed significant up-regulation under all 
three atrophy conditions. These two key genes are Muscle RING (Really Interesting New 
Gene) Finger-1 (MuRF1) and Muscle Atrophy F-box (MAFbx). 
Figure 2.  Northern Blot of MuRF1 and MAFbx expression. MuRF1 and MAFbx gene expression in mice 
are found to increase in expression over time following immobilization, denervation, and hind limb 
suspension. Numbers represent days post-denervation.1   
 
  
Image redacted, paper copy available upon request to home 
institution.
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 Since MuRF1 is quickly and significantly up-regulated following atrophy-
inducing conditions, it is believed to be a major player in the atrophic process via the 
mediation and subsequent proteolytic degradation of target proteins. Indeed, mice that are 
deficient in MuRF1 show significant resistance to muscle atrophy following denervation, 
immobilization, and hind limb suspension.1 Surprisingly, in the dozen years since their 
discovery, very few targets of MuRF1 and MAFbx have been characterized leading to a 
reevaluation of the role of these genes in the atrophy cascade. To this end, data from a 
microarray comparing gene expression profiles in MuRF1-null and wild-type mice under 
neurogenic atrophy conditions was conducted and recently published.6  The results of that 
investigation suggest a possible transcriptional regulatory role for MuRF1.6  Therefore, it 
was the goal of this research to characterize the mechanism by which MuRF1 might act 
as a transcriptional modulator of atrophy-induced gene expression.  
 
Additional Roles of MuRF1in the Muscle Atrophy Cascade 
 There are aspects of both MuRF1 and MAFbx that suggest these genes may play 
additional roles in the atrophy processes. First, these E3 ligases have few known targets 
within skeletal muscle, and of the known targets, one is a muscle-specific transcription 
factor called MyoD1.13 This muscle-specific transcription factor has been shown to be 
targeted for degradation specifically by MAFbx.13 Because this tagging of MyoD1 may 
likely cause other downstream changes in gene expression, this finding supports the 
possibility that these E3 ligases may play a more global role in gene regulation than 
previously thought. Furthermore, MuRF1 has been hypothesized to monoubiquitinate 
some target substrates in cardiac muscle.14 For example, it has recently been suggested 
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that MuRF1 monoubiquinates the peroxisome proliferator-activated receptor alpha 
(PPARα) and regulates its nuclear localization in cardiac muscle.14 In contrast to 
polyubiquitination, monoubiquitination is not commonly believed to cause degradation 
by the proteasome. Monoubiquitination of proteins more commonly serves to change the 
protein’s structure, function, cellular localization, or serves as a signal for the recruitment 
and binding of additional transcription factors.15 The nuclear localization of PPARα in 
response to modification by MuRF1 in cardiac muscle gives precedence that MuRF1 
could act as a potential regulator of protein function beyond its assumed role of simply 
targeting proteins for degradation. Therefore, we hypothesized that MuRF1 may serve to 
tag proteins for further regulation in skeletal muscle in addition to tagging proteins for 
degradation by the proteasome.  
 
Important Structural Characteristics of MuRF1 
 The first step to better understanding the function and regulation of MuRF1 was 
the exploration of the proposed three-dimensional structure of its gene product. The 
different functional domains of MuRF1 suggest that this E3 ligase may have distinct 
functions in muscle. MuRF1 contains a well-characterized RING domain needed for E3 
ligase activity as well as additional domains of interest described below. A RING domain 
is a zinc finger with a consensus sequence of C-X2-C-X[9-39]-C-X[1-3]-H-X[2-3]-C-X2-C-
X[4-48]-C-X2-C, in which C represents a conserved cysteine residue, H represents a 
conserved histidine, and X represents any amino acid. The cysteine and histidine residues 
are involved in interacting with zinc ions, and RING fingers frequently bind 
ubiquitination enzymes as well as target proteins in order to facilitate ubiquitination.16 A 
  
sequence alignment of the 
Figure 3.  
 
Figure 3. Alignment of MuRF1 P
the PubMed database (www.PubMed.org). The proteins were then aligned using sequence alignment tools 
(http://www.ncbi.nlm.nih.gov).  
 
 The RING domain is
participates in the ubiquitina
domains are thought to form additional
protein binding. The acidic c
function; however acidic protein tails may have
proteins, including nuclear translocation
  
 
MuRF1 protein from mouse, rat, and human is shown in
rotein.  MuRF1 protein sequences from mouse, rat and human were downloaded from 
 predicted to perform the catalytic action of MuRF1 as it 
tion processes. The B-box and B-box c
 zinc fingers that may play roles
-terminus of MuRF1 is of special interest and has no known 
 possible roles in the cellular 
.
17, 18
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-terminal (Bbc) 
 in DNA and/or 
location of 
  
 
MuRF1 as a Transcriptional Regulatory Factor in Skeletal Muscle
 Microarray data comparing different
and wild-type mice under denervation conditions suggest that MuRF1 may 
potential transcriptional regulatory factor 
(KO) mouse was engineered via
within the MuRF1 gene.1
MuRF1 gene product was expressed in the wild
gene product was produced in the knockout mouse. This allowed 
different gene products (i.e. 
MuRF1 promoter. 
 MuRF1 gene expression increased in the wild
however, it decreased back to
contrast, the levels of β-galactosidase increased and remained 
animals at 14 days post-denervation (Figure 
 
Figure 4.  Microarray data showing MuRF1 and 
mice.  (A) The MuRF1 gene expression rises following denervation but returns to baseline by day 14
In contrast, β-galactosidase expression remains elevated at 14 days
was conducted on gastrocnemius muscle from wild
14 days (14D) denervation. Each condition was conducted in triplicate and the expression is the average of three 
individual mice. Error bars represent +/
condition.6 
A 
 
ial gene expression profiles in
in skeletal muscle.6 The MuRF1 
 insertion of a β-galactosidase-encoding
  Thus, under control of the endogenous MuRF1 promoter, the 
-type mouse, while the 
for quantification of
β-galactosidase vs MuRF1) under control of the 
-type mice following denerva
 baseline by 14 days following denervation
elevated in the MuRF1
4B). 
β-galactosidase expression in wild-type (WT) and 
 in KO mice. Whole genome expression analysis 
-type (WT) and MuRF1-null (KO) mice following 3 days (3D) and 
- S.E.M of the average expression of the three individual animals from each 
B 
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 MuRF1-null 
act as a 
knock-out 
 lacZ cassette 
β-galactosidase 
 the 
endogenous 
tion; 
 (Figure 4A). In 
-null 
 
MuRF1-null (KO) 
 in WT mice. (B) 
  
 The significance of
galactosidase (β-gal) over time
increase in expression of MuRF1 
denervation in the wild-type mice
wild-type mice) are under the control of 
hypothesize that MuRF1 
 Furthermore, MuRF1 also appears to be necessary for repression of MAFbx 
expression following denervation. MAFbx gene activity increases fo
but returns to baseline by 14 days 
However, in the MuRF1 KO mice, MAFbx expression increases following denervation 
and remains elevated (Figure 
 
 
Figure 5. Microarray data showing MAFbx
expression rises following denervation but returns to baseline by day 14 in WT mice. (B) In contrast, MAFbx 
expression remains elevated at 14 days in KO mice
gastrocnemius muscle from wild
denervation. Each condition was conducted in triplicate and the expression is the average of three 
Error bars represent +/- S.E.M of the average expression of the three individual animals from each condition.
  
 In light of the above 
transcriptional regulatory actions of MuRF1
A 
 this data rests in the maintenance of elevated 
 in the MuRF1 KO animals, as compared to 
and the subsequent return to baseline by 14 days post
. Because β-gal (in the KO mice) and MuRF1
the same regulatory region, it is 
may feedback and repress its own transcriptional activity
llowing denervation 
post-denervation in wild-type mice (Figure 
5B). 
 expression in wild-type (WT) MuRF1-null (KO) mice.  (A) MAFbx gene 
 at 14 days. Whole genome expression analysis was conducted on 
-type (WT) and MuRF1-null (KO) mice following 3 days (3D) and 14 days (14D) 
data, the work described in this thesis explor
 in skeletal muscle tissue. Specifically, 
B 
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expression of β-
the transient 
-
 (in the 
reasonable to 
.  
5A). 
 
individual mice. 
6
 
es the potential 
this 
  
research examines the ability of MuRF1 to negatively transcriptionally regulate itself and 
other atrogenes, including MAFbx. Additionally, because MuRF1 codes for a p
found in skeletal muscle, the potential interaction of MuRF1 with myogenic regulatory 
factors (MRFs), which are also dramatically up
atrophy (i.e. denervation),
 
Myogenic Regulatory Factor 
 The transcriptional regulation of MuRF1 and MAFbx by myogenic regulatory 
factors (MRFs) has been previously analyzed.
in concert with co-activators or co
genes.20     
Figure 6. MAFbx Promoter Alignment.
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database 
(www.ensembl.org) and aligned using the ClustalW algorithm. Identica
highlighted in black. Approximate positions of potential 
alignment : O class, or FoxO, Forkhead binding site (G/A)TAAA(T/C)AA  (
(Diamonds); Muscle specific E box CANGTG (MyoD, etc.)  (
 
 
-regulated in response to neurogenic 
 was also investigated. 
Regulation of MuRF1 and MAFbx Expression
19
  These transcription factors ultimately act 
-repressors to mediate transcription of 
 Promoter sequences from mouse, rat, and human MAFbx genes (5000 base 
l sequences for the indicated regions are 
MRF transcription factor binding sites are 
Ovals); C/EBP TT(G/T)NGNAA 
Large circle) 
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muscle-specific 
 
circled in the 
  
Notably, the proximal promoters of both MuRF1 and MAFbx contain E
sequences (5'-CANNTG-
7).21  The E-boxes in both the MuRF1 and MAFbx proximal promoter
been shown to interact with
myogenin.22  Furthermore, MyoD1 and
neurogenic atrophy of muscle and lead to the induction of MuRF1 and MAFbx 
expression (Figure 8).6 
 
 
Figure 7. MuRF1 Promoter Alignment. Promoter sequences from mou
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database 
(www.ensembl.org) and aligned using the ClustalW algorithm. Identical sequences for the indicate
highlighted in black. Approximate positions of potential transcription factor binding sites are indicated in the 
schematics and highlighted in the alignments
(Hexagons); Muscle specific E box
 
  
 
 
 
3') which are known sites of MRF binding (Figure 6 and Figure 
s
 myogenic regulatory factors, including 
 myogenin levels increase sharply in response to 
se, rat, and human MuRF1 genes (5000 base 
: FoxO, (G/A)TAAA(T/C)AA Ovals); C/EBP TT(G/T)NGNAA 
 CANGTG (MyoD1, etc.)  (Large Circles) 
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 have previously 
MyoD1 and 
 
d regions are 
  
 
Figure 8. Microarray data showing MyoD1 and myogenin expression profiles under atrophy conditions in wild
(WT) and MuRF1-null (KO) mice.
(14D) of denervation. Whole genome expression analysis was conducted on gastrocnemius muscle from wild
(WT) and MuRF1-null (KO) mice following 3 days (3D) and 14 days (14D) 
conducted in triplicate and the expression is the average of three individual mice.
average expression of the three individual animals from each condition.
 
  MyoD1 and myogenin
Basic helix-loop-helix transcription factors are characterized by a protein motif consisting 
of two α-helices connected by a loop. DNA binding is facilitated by t
amino acid residues of one of the loops.
and myogenin bind to the 5'
in myogenic differentiation
of myogenic commitment to the skeletal muscle lineage 
of muscle cells by increasing transcription of p21, 
cell cycle.25 Interestingly, differentiated
knockdown have been shown to d
myoblasts.26 In contrast to MyoD
development of skeletal muscle.
produce mature functional muscle fibers.
A 
 (A) MyoD1 and (B) myogenin expression levels following 3 days (3D) and 14 days 
of denervation. Each condition was 
 Error bars represent +/
6
 
 are basic helix-loop-helix (bHLH) transcription factors
he basicity of the 
23
 Myogenic regulatory factors such as MyoD1 
-CANNTG-3' E-box consensus sequence, and often
 and proliferation.24  For example, MyoD1 is an early marker 
and is known to halt proliferation 
effectively removing cells from the 
 C2C12 mouse myoblast cells under
edifferentiate and re-enter the cell cycle as 
1, myogenin is known to be necessary for proper 
27
 Mice without functional myogenin are unable to 
28
 Myogenin has previously been shown to bind 
B 
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-type 
-type 
- S.E.M of the 
.
22
 
 play roles 
going MyoD1 
proliferating 
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to the MuRF1 and MAFbx promoters and mice without myogenin lose the ability to up-
regulate MuRF1 and MAFbx following denervation.22  
 Current dogma states that MuRF1 and MAFbx regulate skeletal muscle dynamics 
by targeting proteins for degradation, but increasing evidence, including data presented in 
this thesis, suggests that MuRF1 may also function as a muscle-specific transcription 
factor. In light of the information described herein, the regulation of MuRF1 and MAFbx, 
as well as the role of MuRF1 as a transcriptional modulator of atrogene regulation was 
explored. The data in this thesis supports the hypothesis that MuRF1 may act as a 
transcriptional regulator of muscle-specific gene expression.  
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Chapter 2: Transcriptional Repression of Atrogenes by MuRF1 and Myogenic Regulatory 
Factors 
 
 
Introduction 
 Skeletal muscle is highly organized, and is the most abundant tissue by mass 
found in the human body. Skeletal muscle tissue is dynamic and is able to readjust its size 
not only as a response to nutritional status, but also as a response to many other cues 
including stress, mechanical load, neural activity, hormones and growth factors. While 
the main function of skeletal muscle is involved in movement and force generation, 
skeletal muscle also plays a major role in global metabolism and the maintenance of 
energetic homeostasis. For example, during periods of low nutrition, skeletal muscle 
tissue is capable of releasing amino acids that are used in the liver to raise glucose levels 
via gluconeogenesis.29 Skeletal muscle is necessary for normal metabolic processes, and 
recent evidence suggests that skeletal muscle may communicate with the rest of the body 
in order to maintain normal metabolic functions of other tissues and organs.30  
           Skeletal muscle atrophy, or loss of muscle mass, is characterized by a reduction in 
protein content and fiber diameter, and a concomitant decrease in force production. The 
E3-ubiquitin ligase, MuRF1 is hypothesized to be a major regulator of the atrophy 
process. MuRF1 is thought to function in the atrophy cascade since it is expressed 
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predominantly in skeletal muscle, is up-regulated after varied atrophic stressors, and 
deletion of the MuRF1 gene leads to resistance of muscle loss following denervation in 
mice.1, 22, 31 MuRF1 is well characterized as a participant in the proteolytic pathways; 
however, there is evidence that it may play additional roles in muscle plasticity. The 
recently discovered nuclear localization of peroxisome proliferator activated receptor 
alpha (PPARα) via monoubiquitination by MuRF1 in cardiac muscle provides a 
precedence that the ubiquitin ligase activity of MuRF1 may serve to tag proteins for 
further regulation in skeletal muscle in addition to just simply tagging them for 
degradation by the proteasome.14  
 MuRF1 and MAFbx are both up-regulated under numerous conditions of muscle 
atrophy, but these genes have few known targets within skeletal muscle.1 Of the known 
targets, at least one of them is a muscle-specific transcription factor called MyoD1, which 
has been shown to be targeted for degradation by MAFbx.13 Because this may likely 
cause other downstream changes in gene expression, this supports the possibility that 
these atrophy-induced E3 ligases may also play a role in gene regulation under atrophic 
conditions. 
 Microarray data comparing wild-type and MuRF1-null mice under denervation 
conditions suggest that MuRF1 may be a potential transcriptional regulatory factor in 
skeletal muscle.6 MuRF1 gene expression increases in wild-type mice following 
denervation; however, it decreases back to baseline expression levels by 14 days post-
denervation. When the MuRF1 gene is disrupted via insertion of a LacZ cassette, the 
MuRF1 promoter remains active with no subsequent decline to baseline,6 suggesting a 
possible negative-feedback loop in which the MuRF1gene product causes repression of 
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its own promoter.  In addition, MAFbx gene activity also increases following denervation 
and returns to baseline expression levels by 14 days in wild-type mice but remains 
elevated in the MuRF1 KO mice at 14 days post-denervation.6 Therefore, it is reasonable 
to propose that MuRF1 expression may lead to the transcriptional regulation of other 
atrogenes, though the mechanism of this control remains unclear. 
 There are distinct functional domains of the MuRF1 gene product which might be 
implicated in the potential role of MuRF1 as a transcriptional regulatory factor. MuRF1 
contains a well-characterized RING (really interesting new gene) domain needed for E3 
ligase activity. RING fingers frequently bind ubiquitination enzymes as well as target 
proteins, and are thus predicted to perform the catalytic action of E3-ubiquitin ligase 
enzymes.32  The B-box and B-box c-terminal (Bbc) domains of MuRF1 are thought to be 
zinc fingers that may play a role in DNA and/or protein binding.33 The acidic c-terminus 
of MuRF1 is of special interest and has no known function; however acidic protein tails 
may have a role in cellular localization, including nuclear translocation.17, 18  Mutations 
were introduced during our work to inactivate the RING domain or delete the c-terminal 
domain of MuRF1 to better explore the potential roles of these domains in transcriptional 
regulation by MuRF1.  
  The work presented in this thesis examines the potential transcriptional 
regulatory actions of MuRF1 in skeletal muscle atrophy. Specifically, the ability of 
MuRF1 to negatively transcriptionally regulate itself and other atrogenes, including 
MAFbx, was explored using  reporter assays to  measure MuRF1 and MAFbx expression 
under various conditions, including in response to overexpression of MuRF1. 
Additionally, because MuRF1 codes for a protein found in skeletal muscle, the potential 
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interaction of MuRF1 with myogenic regulatory factors (MRFs) was also explored. 
Finally, in order to determine if MuRF1 catalytic activity was necessary for the ability of 
MuRF1 to modulate transcription, mutations were introduced in order to inactivate the 
RING domain or delete the carboxyl-terminal domain. The data presented below provides 
an analysis of the role of MuRF1 as a transcriptional regulator of atrogenes. This thesis 
proposes a new function for MuRF1 in the skeletal muscle atrophy process beyond its 
classical role as a post-translational ubiquitinator of target proteins.  
 
Materials and Methods 
 
 Cell Culture 
 C2C12 mouse myoblast cells were obtained from a cryostored stock (American 
Type Culture Collection, Manassas, VA). The cells were thawed, and subsequently 
grown in a 10 cm cell culture dish in 10 mL of proliferation media (DMEM 
supplemented with 10% FBS, Pen/Strep, nonessential amino acids, and gentamycin) at 
37°C in a 6% CO2 humidified chamber. 
 
Transfections and SEAP Reporter Assays  
 C2C12 cells were plated at a density of 50,000 cells/well into 12-well plates and 
cultured until an approximate confluency of 70-90% was reached. Prior to transfection, 
media was aspirated from cells, and 1 mL of fresh proliferation media was added. A total 
of 1 µg of DNA/well was transiently transfected into each well of the 12-well plates. The 
transfected DNA cocktail consisted of 250 ng/well of reporter construct, 125 ng/well of 
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pCMV-β-Galactosidase and 125 ng/well of expression plasmids (i.e., pcDNA3.1-MuRF1, 
pcDNA3.1-MuRF1-RING-mut, pcDNA3.1-MuRF1-c-term-mut, pcDNA3.1-MyoD1, 
and/or pcDNA3.1-myogenin), and pBluescript as filler to bring to 1 ug/well total DNA. 
The DNA mixtures were then added to TransIT-LT1 Transfection Reagent (MirusBio, 
Madison, WI) diluted in unsupplemented DMEM according to the manufacturers 
protocol.  The DNA/LT-1 solutions were mixed gently, and incubated at room 
temperature for 30 min. Following the 30 minute incubation, 75 µL of DNA/LT-1 
mixture for each reaction condition was added to each well of C2C12 cells in a 12-well 
plate. The C2C12 cells were incubated at 37°C and 6% CO2 for 24 hours, and then 1 mL 
of fresh differentiation media (DMEM with 2% FBS, Pen/Strep, nonessential amino acids 
and gentamycin) was added to each well to induce myoblast differentiation. Levels of 
secreted alkaline phosphatase (SEAP) were measured at 24, 48, and 72 hours post-media 
change using a commercial protocol from Clontech Laboratories according to the 
manufacturer’s instructions (Mountain View, CA.). The C2C12 myotubes were lysed at 
the conclusion of each experiment, and SEAP numbers were normalized to β-
galactosidase activity to correct for variations in transfection efficiency. Each condition 
was done in triplicate and error reflects +/- standard deviation. 
 
Promoter Cloning of MuRF1 and MAFbx  
 Cloning of the pSEAP-MuRF1-Pro500, pSEAP-MuRF1-Pro1000, pSEAP-
MuRF1-Pro2000, pSEAP-MuRF1-Pro5000, pSEAP-MAFbx-Pro500, pSEAP-MAFbx-
Pro1000, pSEAP-MAFbx-Pro2000, and pSEAP-MAFbx-Pro5000 plasmids has been 
previously described. 34   The 500 bp, 1000 bp, 2000 bp, and 5000 bp promoter fragments 
  
19 | P a g e  
 
were amplified by PCR using BAC clones purchased from CHORI (Oakland, CA). The 
resulting PCR product was cloned into the SEAP2-Basic reporter vector (Clontech 
Laboratories).  
 
 
 
MuRF1 cDNA Cloning 
 RNA was extracted from homogenized C2C12 mouse muscle cells using RNeasy 
columns per the manufacturer’s protocol (Qiagen, Valencia, CA).  Mouse cDNA was 
reverse-transcribed from the mouse mRNA using the following conditions: oligo (dT) 
primers (500 µg/ml) and dNTP mixture (2.5 mM) were combined with mouse mRNA    
(1 ng) with nuclease-free sterile water. The mixture was incubated at 65°C for 5 minutes 
and then incubated on ice for 1 minute. The mixture was briefly centrifuged and First-
Strand Buffer (Invitrogen Corporation, Carlsbad, CA), DTT (0.1 M), and Ribonuclease 
Inhibitor were added per manufacturer’s instructions. The mixture was briefly mixed and 
incubated at 37°C for 2 minutes, followed by the addition of Moloney Murine Leukemia 
Virus (M-MLV) Reverse Transcriptase (Invitrogen Corporation). The reaction was then 
incubated at 37°C for 50 minutes followed by heat inactivation at 70°C for 15 min. The 
MuRF1 cDNA was amplified via PCR using the C2C12 and gene specific primers, cloned 
into the EcoRI/XbaI sites of pcDNA3 and sequenced to confirm the identity of the 
cDNA. 
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Generation of MuRF1 Mutants 
 The MuRF1 DNA and protein sequences were downloaded from the PubMed 
database (www.PubMed.org). The MuRF1 protein sequences for rat, mouse and human 
were then aligned using sequence alignment tools (http://www.ncbi.nlm.nih.gov). These 
alignments were then used to identify conserved amino acids for site-directed 
mutagenesis. Site-directed mutagenesis reactions were performed as instructed in the 
manufacturer's protocol (Stratagene, La Jolla, California). Site-directed mutagenesis 
primers were designed and used to introduce mutations in the RING domain or the acidic 
c-terminal tail region of the MuRF1 gene.  The c-terminal MuRF1 mutant was created 
using the following primer sequences:  
 
 
FWD: 3’-CTTTGGGACAGATTAGTTAGGAGGAGGAGGAGGAG-5’,  
REV: 3’-CTCCTCCTCCTCCTCCTACTAATCTGTCCCAAAG-5’. The MuRF1 RING 
mutant was generated using the following primer sequences: 
FWD: 3’CCAACACCAACCTCAGCCGGAAGAGTGCCAACGACATC-5’ and  
REV: 3’-GATGTCGTTGGCACTCTTCCGGCTGAGGTTGTGTTGG-5’.  The resulting 
clones were sequenced to confirm introduction of the correct mutation. 
 
Generation of E-box Mutations in the MuRF1 Promoter 
 The two E-boxes identified in the MuRF1 proximal promoter were mutated via 
site-directed mutagenesis. Site-directed mutagenesis was performed on the MuRF1-
Pro500-SEAP reporter plasmid as instructed in the manufacturer's protocol (Stratagene). 
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The primer sequences used to mutate the E-box at position -156 in the MuRF1 promoter 
were: 
 FWD-5’-GGCCCTCTCAGATCCAGGCAGGGATG-3’ and 
 REV-3’-GCTCATCCCTGCCTGGGACTGAGAGGGCC-5’.  
The primer sequences used to mutate the E-box at position -57 in the MuRF1 promoter 
were  FWD-5’-CCTCCTGGGGCTCCTGGGACAGAGGTGCAGC-5’ and 
 REV-3’- GCTGCACCTCTGTCCCAGGAGCCCCAGGAGG-3’.  
The resulting DNA was sequenced to confirm introduction of the correct mutation. 
 
Construction of a Concatemerized 4X E-box Reporter 
             Four discrete E-boxes were cloned upstream of a minimal SV40 promoter fused 
to the SEAP reporter gene (Figure 9). Oligonucleotides with sequences of FWD-5’-
CGCGCCTGCATGTGATAT-3’ and REV-5’-CGCGAGATCACATGCAGG-3’ were 
end-phosphorylated using T4 Polynucleotide Kinase and then annealed by mixing and 
heating to 95°C for two minutes and slowly cooling to 25°C for 45 minutes in a 
thermocycler. The annealed oligonucleotides were then ligated into the MluI site in front 
the SV40 minimal promoter of linearized pSEAP2-Promoter plasmid (Clontech) and 
sequenced to confirm insertion and orientation. 
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 Western Blotting 
  C2C12 cells were transfected with either pcDNA-MuRF1 or pcDNA-MuRF1-
RING mutant expression plasmids. The cells were harvested at 72 hours post-transfection 
and lysed using 500 µL of Universal Lysis Buffer (ULB)  (50 mM Tris, 150 mM NaCl, 
50 mM NaF, 0.5% Igepal, 1 mM PMSF, 1mM DTT, 10mM β-glycerophosphate , 2 mM 
Sodium Molybdate and a protease inhibitor cocktail) . The cells were then incubated on 
ice for 30 minutes and centrifuged at 4°C for 5 minutes at 18,000 × g.  The supernatant 
was then transferred to new 1.5mL Eppendorf tubes and stored at -80˚C. Protein 
concentrations were determined using a modified Bradford protein assay method 
according to the manufacturer’s protocol (BioRad, Hercules, CA). Total protein (200µg) 
was separated on an SDS-PAGE gel, and then transferred overnight to a polyvinylidene 
difluoride (PVDF) membrane. The membrane was blocked for one hour with a blocking 
solution of 5% milk + 0.05% Tween in Tris Buffered Saline (TTBS). The blocked 
membrane was then probed by a protein-specific primary antibody. Commercially 
available primary antibodies for MyoD1 (M-318, rabbit, Santa Cruz Biotechnology, Inc.,) 
and myogenin (F5D, mouse, Santa Cruz Biotechnology, Inc.,) were incubated with the 
membrane at a concentration of 1:500 for 1 hr with shaking. Following four washes with 
TTBS, the membrane was incubated with an appropriate secondary antibody at a 1:5000 
concentration for 1 hour and then washed in TTBS. Signal development closely followed 
manufacturer’s instructions for the Pierce ECL Western Blotting kit and imaged using the 
Typhoon Imager (Thermoscientific, Rockford, IL.). 
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Results  
 
Transcriptional Repression of MAFbx Expression by MuRF1 
 The ability of  MuRF1 to regulate the expression of MAFbx was first tested using 
a series of MAFbx promoter constructs, and the results revealed that the MAFbx reporter 
constucts are repressed by MuRF1 ectopic expression. A reporter plasmid containing a 
500 bp MAFbx proximal promoter fragment fused to SEAP (MAFbx-Pro500) was 
cotransfected into C2C12 cells with or without a MuRF1 expression plasmid. As shown in 
Figure 9, the MAFbx 500 bp promoter shows a significant decrease in activity in cells 
overexpressing MuRF1. 
 
Figure 9.  MAFbx-Pro500 reporter shows transcriptional repression in response to overexpression of MuRF1. C2C12 
myoblasts were transfected with a reporter construct consisting of the MAFbx-500bp promoter fragment fused to the 
SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and an expression plasmid for MuRF1. The myoblasts 
were maintained in standard differentiating culture media. Samples of media were taken at 24 hr intervals and 
measured for SEAP activity. The samples were normalized with β-galactosidase activity to correct for variation in 
transfection efficiency. Each condition was done in triplicate and error bars represent standard deviation (-/+ S.D.) of 
the mean.  
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Cooperative Regulation of MAFbx Expression by MuRF1 and Myogenic Regulatory 
Factors 
 MuRF1 negatively regulates the transcriptional activity of MAFbx as shown in 
Figure 9 above. Since the MAFbx proximal promoter contains a functional E-box and has 
previously been shown to be up-regulated by the myogenic regulatory factors MyoD1 
and myogenin,22 we next tested if MuRF1 overexpression might modulate MRF 
transcriptional regulation of MAFbx. These experiments show that MyoD1 causes 
activation of the MAFbx-Pro500 reporter. However, co-overexpression with MuRF1 not 
only reversed MyoD1 activation, but also caused a cooperative repression of the MAFbx-
Pro500 reporter (Figure 10A). In addition, the MuRF1/MRF combinatorial effect was 
also observed when the MAFbx-Pro500 reporter was transfected into cells along with 
MuRF1 and myogenin expression plasmids. Co-overexpression of MuRF1 with 
myogenin also resulted in significant repression of the MAFbx-Pro500 reporter activity 
(Figure 10B).  
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Figure 10. MuRF1 and MRFs Cooperatively Regulate MAFbx Reporter Activity. The MAFbx-Pro500 shows 
transcriptional repression in response to co-overexpression of MuRF1 and (A) MyoD1 and (B) myogenin. C2C12 
myoblasts were transfected with a reporter construct consisting of the MAFbx-500bp promoter cloned into the SEAP2-
Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for MuRF1 alone or in combination with 
MyoD1 or myogenin. The myoblasts were maintained in standard differentiating culture media. Samples of media were 
taken at 24 hr intervals and measured for SEAP activity. The samples were normalized to β-galactosidase activity to 
correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars represent 
standard deviation (-/+ S.D.) of the mean.    
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 The MuRF1/MRF repressive effect was also observed when larger regions (i.e. 
1000 bp, 2000 bp and 5000 bp fragments) of the MAFbx proximal promoter were 
evaluated (Figure 11 and Figure 12). For all fragment sizes of the MAFbx promoter that 
were evaluated, overexpression of MuRF1 caused significant transcriptional repression. 
Furthermore, overexpression of MyoD1 or myogenin caused transcriptional activation of 
the 1000 bp MAFbx promoter but caused repression of the 2000 bp and 5000 bp MAFbx 
reporter constructs. In a pattern similar to that seen in the MAFbx 500 bp promoter, 
cooperative repression of the MAFbx 1000, 2000 and 5000 bp promoter fragments by 
MuRF1 in combination with MyoD1 (Figure 11) or myogenin (Figure 12) was observed. 
In all cases, the repressive trend on the MAFbx reporter constructs by the co-
overexpression of MuRF1/MyoD1 or MuRF1/myogenin was significantly greater than 
that caused by any factor individually. 
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Figure 11. MuRF1and MyoD1 cooperatively regulate larger MAFbx promoter fragments. The (A) 1000 bp, (B) 2000 
bp, and (C) 5000 bp promoters of MAFbx show cooperative repression when MyoD1 is expressed in combination with 
MuRF1. C2C12 myoblasts were transfected with a reporter construct consisting of either the MAFbx 1000 bp, 2000 bp, 
or 5000bp promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression 
plasmids for MyoD1 and/or MuRF1. The myoblasts were maintained in standard culture media. Samples of media were 
taken at 72 hrs and measured for SEAP activity. The samples were normalized to β-galactosidase activity to correct for 
variation in transfection efficiency. Each condition was done in triplicate and the error bars represent standard deviation 
(-/+ S.D.) of the mean. 
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Figure 12. MuRF1 and myogenin cooperatively regulate larger MAFbx promoter fragments. The (A) 1000 bp, (B) 
2000 bp, and (C) 5000 bp promoters of MAFbx show cooperative repression when myogenin is expressed in 
combination with MuRF1. C2C12 myoblasts were transfected with a reporter construct consisting of either the MAFbx 
1000 bp, 2000 bp, or 5000bp promoter clone into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and 
expression plasmids for myogenin and/or MuRF1. The myoblasts were maintained in standard culture media. Samples 
of media were taken at 72 hrs and measured for SEAP activity. The samples were normalized to β-galactosidase 
activity to correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars 
represent standard deviation (-/+ S.D.) of the mean. 
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Negative Transcriptional Regulation of MuRF1 Reporter Activity by MuRF1 
 Previous results suggest that MuRF1 may participate in its own transcriptional 
regulation.6 Therefore, we tested the effects of ectopic expression of MuRF1 on MuRF1 
reporter constructs in C2C12 cells and observed transcriptional repression of a 500 bp 
promoter construct (Figure 13). 
 
Figure 13. MuRF1 transcriptional regulation of MuRF1 reporter activity. The MuRF1-Pro500 reporter construct shows 
transcriptional repression in response to overexpression of MuRF1. C2C12 myoblasts were transfected with a reporter 
construct consisting of the MuRF1 500bp promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression 
plasmid, and an expression plasmid for MuRF1. The myoblasts were maintained in standard differentiating culture 
media. Samples of media were taken at 24 hr intervals and measured for SEAP activity. The samples were normalized 
to β-galactosidase activity to correct for variation in transfection efficiency. Each condition was done in triplicate and 
the error bars represent standard deviation (-/+ S.D.) of the mean.    
 
 The MuRF1 proximal promoter has two functional E-boxes that have previously 
been shown to be necessary for proper MuRF1 expression, and have been shown to bind 
MyoD1 and myogenin.19, 22 Therefore, we tested the ability of MyoD1 and myogenin to 
regulate MuRF1 reporter activity in conjunction with MuRF1 ectopic expression. The 
MuRF1 500 bp promoter showed significant activation by both myogenin and MyoD1 
(Figure 14), with overexpression of myogenin causing a 10-fold increase in MuRF1 
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promoter activity, while MyoD1 overexpression led to a 50-fold increase in MuRF1 
promoter activity. Furthermore, co-overexpression of MuRF1 and MyoD1 reduced 
MyoD1-induced MuRF1 promoter activity from 50-fold induction to approximately 10-
fold induction (Figure 14A), while this MuRF1 reporter showed complete loss of 
activation in response to ectopic expression of MuRF1 in combination with myogenin 
overexpression (Figure 14B).  
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Figure 14. MuRF1 and MRFs cooperatively regulate MuRF1 reporter activity. The MuRF1-Pro500 reporter shows 
transcriptional repression in response to co-overexpression of MuRF1 and (A) MyoD1 or (B) myogenin. C2C12 
myoblasts were transfected with a reporter construct consisting of the MuRF1-500bp promoter cloned into the SEAP2-
Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for MuRF1 alone or in combination with 
myogenin or MyoD1. The myoblasts were maintained in standard differentiating culture media. Samples of media were 
taken at 24 hr intervals and measured for SEAP activity. The samples were normalized to β-galactosidase activity to 
correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars represent 
standard deviation (-/+ S.D.) of the mean. 
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 The MuRF1/MRF combinatorial repressive effect was also observed when larger 
regions (i.e. 1000 bp, 2000 bp and 5000 bp fragments) of the MuRF1 proximal promoter 
were evaluated. The effects of MyoD1 and myogenin either alone or in combination  with 
MuRF1 on the activity of the 1000 bp, 2000 bp, and 5000 bp promoter regions of MuRF1 
were tested, and while the larger sizes of the MuRF1 promoter showed increased general 
expression, they showed identical patterns of regulation compared to the 500 bp 
promoter. In each case, the MuRF1 promoter fragments showed induction by either 
MyoD1 or myogenin alone (Figure 15 and Figure 16, respectively), but this activation 
was greatly reduced or completely abolished when MyoD1 or myogenin was expressed in 
combination with MuRF1.  
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Figure 15. MuRF1 and MyoD1 cooperatively regulate larger MuRF1 promoter fragments. The (A) 1000, (B) 2000, and 
(C) 5000 bp promoters of MuRF1 show marked induction by MyoD1 in C2C12 cells, which is largely abolished when 
MyoD1 is overexpressed in combination with MuRF1 C2C12 myoblasts were transfected with a reporter construct 
consisting of either the MuRF1 1000, 2000, or 5000bp promoter cloned into the SEAP2-Basic plasmid, a β-
galactosidase expression plasmid, and expression plasmids for MyoD1 and/or MuRF1. The myoblasts were maintained 
in standard culture media. Samples of media were taken at 72 hrs post-media change and measured for SEAP activity. 
The samples were normalized to β-galactosidase activity to correct for variation in transfection efficiency. Samples 
were done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean. 
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Figure 16. MuRF1 and myogenin cooperatively regulate larger MuRF1 promoter fragments. The (A) 1000, (B) 2000, 
and (C) 5000 bp promoters of MuRF1 show marked induction by myogenin in C2C12 cells, which is completely 
abolished when myogenin is overexpressed in combination with MuRF1 C2C12 myoblasts were transfected with a 
reporter construct consisting of either the MuRF1 1000, 2000, or 5000 bp promoter cloned into the SEAP2-Basic 
plasmid, a β-galactosidase expression plasmid, and expression plasmids for myogenin and/or MuRF1. The myoblasts 
were maintained in standard culture media. Samples of media were taken at 72 hrs post-media change and measured for 
SEAP activity. The samples were normalized to β-galactosidase activity to correct for variation in transfection 
efficiency. Samples were done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean. 
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E-box Sequence is Sufficient for MuRF1/MRF 
 To further characterize the role of the E
promoter, a series of four concatemerized E
at position -156 in the MuRF1 regulatory region were cloned in front of a minimal SV40 
promoter that contains no enhancers (
either MyoD1 (Figure 18A) or myogenin (Figure 18B) caused a significant repression of 
the 4x-Ebox-SEAP reporter.
Figure 17. An illustration showing the 
MuRF1 E-boxes cloned upstream of the SV40 Early Promoter 
directions of the arrows represent the 5’
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Figure 18. The concatemerized 4x-Ebox-SEAP reporter exhibits cooperative repression by MuRF1 and (A) MyoD1 or 
(B) myogenin. C2C12 myoblasts were transfected with a reporter construct consisting of the concatemerized 4X-Ebox 
construct cloned into the SEAP2-Promoter plasmid, a β-galactosidase expression plasmid, and expression plasmids for 
MyoD1, myogenin, and/or MuRF1. The myoblasts were maintained in standard culture media. Samples of media were 
taken at 24 hr intervals and measured for SEAP activity. The samples were normalized to β-galactosidase activity to 
correct for variation in transfection efficiency. Each condition was done in triplicate and the error bars represent 
standard deviation (-/+ S.D.) of the mean. 
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MuRF1 Catalytic Activity is Necessary for MuRF1-mediated Reversal of MRF-induced 
Reporter Gene Activity  
 Overexpression of MuRF1 has consistently resulted in little to no repression of 
the transcriptional activity of the 4x-Ebox-SEAP reporter, but consistently represses this 
construct when co-overexpressed with MyoD1 or myogenin (Figure 18). However, the 
MuRF1/MyoD1 cooperative repression of the 4X-Ebox-SEAP reporter is largely 
abrogated when MyoD1 is co-overexpressed with a MuRF1-RING-mutant (Figure 19A).  
In addition, overexpression of myogenin alone caused a decrease in transcriptional 
activity of the 4X-Ebox-SEAP reporter construct, while co-overexpression of myogenin 
with MuRF1 resulted in a dramatic cooperative repression of the reporter (Figure 19B). 
Furthermore, the overexpression of myogenin in combination with the MuRF1-RING-
mutant caused no repression of the 4X-Ebox-SEAP reporter (Figure 19B).  
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Figure 19. MuRF1 and MRF cooperative repression of the 4X-Ebox-SEAP reporter is abrogated when (A) MyoD1 or 
(B) myogenin is co-overexpressed with the MuRF1-RING-mutant. C2C12 myoblasts were transfected with a reporter 
construct consisting of a concatemerized 4X-E-box cloned into the SEAP2-Promoter plasmid, a β-galactosidase 
expression plasmid, and expression plasmids for MuRF1, MuRF1-RING-mutant, MyoD1 and/or Myogenin. The 
myoblasts were maintained in standard culture media. Samples of media were taken at 72 hrs post-media change and 
measured for SEAP activity. The samples were normalized to β-galactosidase activity to correct for variation in 
transfection efficiency. Each condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.) 
of the mean. 
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 In order to determine if MuRF1 catalytic activity is also required for cooperative 
repression of MuRF1 reporter activity, cells were transfected with the MuRF1-Pro500 
reporter construct and MyoD1 along with MuRF1 or the MuRF1-RING mutant. 
Overexpression of MyoD1 again caused induction of the promoter construct, which was 
partially abrogated by co-overexpression with MuRF1. This abrogation of activation was 
not observed when MyoD1 was co-overexpressed with the MuRF1-RING-mutant (Figure 
20A). Furthermore, overexpression of myogenin alone caused a significant increase in 
the transcriptional activity of the MuRF1-Pro500 construct, which was completely 
reversed when myogenin was co-overexpressed in combination with MuRF1. In contrast, 
overexpression of myogenin in combination with the MuRF1-RING-mutant actually 
caused an increase in reporter transcriptional activity (Figure 20B).  
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Figure 20. MuRF1 and MRF cooperative repression of the MuRF1-Pro500 reporter is abrogated when (A) MyoD1 or 
(B) myogenin is co-overexpressed with the MuRF1-RING-mutant. C2C12 myoblasts were transfected with a reporter 
construct consisting of MuRF1 500 bp promoter fragement cloned into the SEAP2-Basic plasmid, a β-galactosidase 
expression plasmid, and expression plasmids for MuRF1, MuRF1-RING-mutant, MyoD1 and/or Myogenin. The 
myoblasts were maintained in standard culture media. Samples of media were taken at 72 hrs post-media change and 
measured for SEAP activity. The samples were normalized to β-galactosidase activity to correct for variation in 
transfection efficiency. Each condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.) 
of the mean. 
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The MuRF1 Acidic Carboxyl-Terminal Tail is Not Required for MuRF1-mediated 
Reversal of MRF-induced Reporter Gene Activity  
 Truncation of the acidic c-terminus of the MuRF1 protein did not significantly 
alter the cooperative repression of the 4X-Ebox-SEAP reporter by MuRF1 and MyoD1. 
As shown previously, the transcriptional activity of this reporter is repressed in response 
to ectopic expression of MyoD1 alone, while this repression is further increased when 
MyoD1 was co-overexpressed in combination with MuRF1 (Figure 21). Furthermore, 
overexpression of MyoD1 in combination with the MuRF1-c-terminal mutant was 
indistinguishable from co-overexpression of MyoD1 with full-length MuRF1 (Figure 21).  
 
Figure 21. The MuRF1-c-terminal mutant in combination with MyoD1 cooperatively represses the 4X-Ebox-SEAP 
reporter. C2C12 myoblasts were transfected with a reporter construct consisting of the concatemerized 4X-E-boxes 
cloned into the SEAP2-Promoter plasmid, a β-galactosidase expression plasmid, and expression plasmids for MuRF1, 
MuRF1-c-terminal-mutant, and/or MyoD1. The myoblasts were maintained in standard culture media. Samples of 
media were taken at 72 hr and measured for SEAP activity. The samples were normalized to β-galactosidase to correct 
for variation in transfection efficiency. Samples were done in triplicate and the error bars represent standard deviation 
(-/+ S.D.) of the mean. 
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mutant. As shown previously, overexpression of MyoD1 caused a significant increase in 
transcriptional reporter activity, which was completely abolished when MyoD1 was co-
overexpressed in combination with MuRF1. Furthermore, overexpression of the C-
terminal MuRF1 mutant alone showed no appreciable difference compared to the effect 
of full-length MuRF1 on the transcriptional activity on the MuRF1-Pro500 reporter 
construct, while co-overexpression of the MuRF1 c-terminal mutant with MyoD1 also 
showed no significant differences on the MuRF1-Pro500 reporter when compared to 
MuRF1/MyoD1 co-overexpression (Figure 22).  
 
 
Figure 22. The MuRF1-c-terminal mutant in combination with MyoD1 cooperatively represses the MuRF1-Pro500 
reporter. C2C12 myoblasts were transfected with a reporter construct consisting of the MuRF1 500 bp promoter 
fragment cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for 
MuRF1, MuRF1-c-terminal-mutant, and/or MyoD1. The myoblasts were maintained in standard culture media. 
Samples of media were taken at 72 hr and measured for SEAP activity. The samples were normalized to β-
galactosidase to correct for variation in transfection efficiency. Samples were done in triplicate and the error bars 
represent standard deviation (-/+ S.D.) of the mean. 
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Ectopic Expression of MuRF1 Does Not Alter Endogenous Myogenin Protein Levels 
 Myogenin protein levels were unchanged in C2C12 cells overexpressing either 
MuRF1 or the MuRF1-RING mutant. This data suggests that the mechanism by which 
MuRF1 modulates MRF activity is not simply due to destabilizing these myogenic 
regulatory factors (Figure 23). 
 
 
 
Figure 23. Similar levels of myogenin protein observed in C2C12 cells over-expressing MuRF1 and in C2C12 cells over-
expressing the MuRF1-RING-mutant. C2C12 myoblast cells were transfected with an expression plasmid containing 
either MuRF1, or the MuRF1-RING-mutant. The myoblasts were maintained in standard culture media and harvested 
at 72 hours. Western blotting was performed on 100µg and 200µg of total protein using antibodies against myogenin. 
 
Discussion 
 MuRF1 expression increases in response to an array of atrophy-inducing 
conditions;1 however, the mechanism of the transcriptional regulation of this gene is still 
not completely understood. Furthermore, the results from this study suggest that MuRF1 
may also play a role in the transcriptional regulation of a subset of atrogenes, including 
itself. MuRF1 has been shown through this research to be an inhibitive transcriptional 
regulator of the MAFbx and MuRF1 gene. These results are consistent with recent 
microarray data in which MuRF1-null animals showed differential gene expression 
compared to wild-type (WT) littermates.6 MuRF1-null animals exhibited continued 
elevation of MuRF1 (evidenced by increased β-gal expression in the MuRF1-null mice) 
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and MAFbx expression following denervation, while the expression of these genes 
returned to baseline in the WT mice following denervation.  MuRF1 has long been 
described as a marker for muscle atrophy, given that the expression of MuRF1 increases 
in response to numerous atrophic stimuli1; however, the present study expands the role of 
MuRF1 to include that of a regulator of atrophy-induced gene expression. 
 Furthermore, this thesis provides insight into the mechanisms by which MuRF1 
inhibits atrophy-induced gene expression. Specifically, we show that MuRF1 acts, at least 
in part, via direct and/or indirect modulation of the MyoD-family of myogenic regulatory 
factors, including MyoD1 and myogenin.  MyoD1 and myogenin are basic helix-loop-
helix proteins that have been shown to bind E-boxes in the promoters of muscle specific-
genes.22 In addition, we have confirmed transcriptional activation of MuRF1 and MAFbx 
by MyoD1 and myogenin; however, we demonstrate for the first time here that MuRF1 
cooperates with both MyoD1 and myogenin to repress MuRF1 and MAFbx reporter gene 
expression.  These findings support the microarray data showing that both MAFbx and 
MuRF1 expression remain elevated in MuRF1-null mice, suggesting that the MuRF1 
gene product is necessary for returning atrogene expression to baseline levels following a 
atrophic stimulus. Our findings suggest that MuRF1 acts as a modulator of myogenic 
regulatory factors, although the exact mechanism is still unclear. Intriguingly, MuRF1 
has been previously shown to regulate the localization of PPARα in cardiac muscle via 
monoubiquitination providing a possible mechanism by which MuRF1 might impact 
MRF function.14 
 While the exact mechanism of MuRF1 regulation of atrophy-responsive genes via 
modulation of MyoD1 and myogenin is not yet known, there are multiple possible 
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explanations. It is possible that MuRF1 serves to a) directly interact with MyoD1 and 
myogenin and alter their function, stability or cellular localization, b) ubiquinate  MyoD1 
and myogenin as means to change their function, stability, or cellular localization, c) 
target recruitment of additional transcription factors to the promoters of atrophy-induced 
genes, or d) interact with or recruit additional proteins which themselves associate with 
the promoters of muscle-specific genes.5 
 The latter possibility is of special interest given that recent research has shown 
that many myogenic regulatory factors, including MyoD1 and myogenin, associate with 
proteins such as HEB (TF12) and the E2A gene products E12 and E47. It has been well 
established that members of the MyoD family of transcription factors, including MyoD1 
and myogenin, function as heterodimers with more universally-expressed E proteins. 
Multiple myogenic regulatory factors have been shown to associate with E proteins in a 
sequential manner at numerous muscle-specific genes including muscle creatine kinase 
(Ckm), desmin (Des), fast-twitch skeletal muscle troponin I, type 2 (Tnni2),  leimodin 2 
(lmod2), and titin cap (Tcap).5 While neither MuRF1 nor MAFbx were included in the 
above study, we predict that these genes may also be regulated in part by the ubiquitously 
expressed E proteins in association with MRFs, due to the presence of conserved E boxes 
in both the MuRF1 and MAFbx proximal promoter. Interestingly, MuRF1-null mice 
show differential gene expression in cardiac muscle, with a majority of the differentially 
regulated genes being E2F regulated.35  The data presented in this research suggest that 
MuRF1 gene expression may modulate the activity, recruitment, or stability of myogenic 
regulatory factors and/or their known binding partners.  
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 While the exact mechanism of MuRF1-mediated repression of muscle-specific 
genes through the potential modulation of MRFs remains less than complete, the data 
presented here suggests that the RING domain of MuRF1 may be important. 
Overexpression of the catalytically dead MuRF1 RING mutant in combination with 
either MyoD1 or myogenin failed to cause any significant repression of the MuRF1 
reporter gene. This suggests that ubiquitin tagging of MRFs by MuRF1 might be a 
possible explanation for MuRF1-mediated regulation of MyoD1 and myogenin function 
in muscle cells.  It is also possible that MyoD1 and myogenin may recruit MuRF1 to the 
promoters of target genes and allow for modification of other participants in the 
transcriptional regulatory process. This MuRF1-mediated tagging may cause a change in 
association and/or recruitment of the MRFs and/or their E protein binding partners to E-
box elements within target gene regulatory regions. This possibility is supported by our 
data showing a complete loss of cooperative repression of the synthetic 4X-Ebox-SEAP 
reporter when the MuRF1-RING mutant is over-expressed in combination with MyoD1 
or myogenin. Furthermore, it is unlikely that potential MRF ubiquitin tagging catalyzed 
by MuRF1 causes degradation of these transcription factors, as the level of myogenin 
protein in cells overexpressing MuRF1 closely mirrors that seen in cells over-expressing 
the MuRF1-RING mutant.   
 The catalytic RING domain of MuRF1 may participate in an array of functions in 
addition to the interaction between MuRF1 and myogenic regulatory factors.  Thus, there 
are additional possible explanations for the data presented in this thesis.  For example, the 
loss of cooperative repression of the MuRF1 reporter construct and of the 4X-Ebox 
reporter construct by MRFs and the MuRF1-RING mutant may also be explained by a 
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change in the cellular localization of the MuRF1 protein following mutation. Previous 
work has shown that the RING domain may function in nuclear localization of the 
MuRF1 protein, likely through interaction with SUMO-3 (small ubiquitin-related 
modifier-3,) which has itself been shown to participate in nuclear import.36, 37  Since it is 
possible that mutation of the 3rd and 4th cysteine residues in the RING domain of MuRF1 
may impact the localization of MuRF1 in the cell, future work to verify this possibility 
will involve tagging the MuRF1 protein and the MuRF1-RING mutant with a GFP tag in 
order to monitor cellular localization. Finally, in contrast to the RING domain, the acidic 
c-terminal domain of MuRF1 is not suggested by this research to be integral to the 
cooperation between MuRF1 and the myogenic regulatory factors in regulating gene 
activity. This is supported by the observation that the 4X-Ebox and the MuRF1 reporter 
constructs both show similar activity patterns in response to co-overexpression of the 
MuRF1 c-term mutant or full-length MuRF1 with MyoD1 or myogenin. In summary, the 
present study provides exciting new evidence supporting the hypothesis that MuRF1 may 
act as a major transcriptional regulator of atrophy-induced gene expression. Specifically, 
we demonstrate here that  1) MuRF1 acts as a transcriptional modulator  of atrophy-
regulated genes, including itself, 2) MuRF1 does so in part via either direct or indirect 
interactions with myogenic regulatory factors, and 3) specific domains of the MuRF1 
gene product likely play an important roles in mediating this interaction. 
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Conclusions and Future Directions 
 This thesis provides new evidence supporting the hypothesis that MuRF1 acts as a 
major regulator in skeletal atrophy.  Future  work on this project should include 
continued exploration of the potential interaction of MuRF1 with myogenic regulatory 
factors and E proteins. It is conceivable that the synergistic repression of the MuRF1 and 
MAFbx promoters by the combination of MuRF1 and MyoD1 or myogenin is mediated 
by a ubiquitination effect by MuRF1. The stability and ubiquitination status of MyoD1, 
myogenin, and associated E proteins could be evaluated via co-immunoprecipitation 
experiments in cells that are over-expressing MuRF1 or the MuRF1-RING mutant. 
Furthermore, immunoprecipitation of MyoD1 and myogenin from C2C12 cells that 
ectopically express MuRF1 or MuRF1 RING mutant, followed by western blotting for 
ubiquitin would help determine if MuRF1 is actually tagging these proteins in the cell. 
  In addition, future work using Chromatin Immunoprecipitations (ChIPs) of the 
MuRF1 and MAFbx promoters with antibodies against MyoD1 and myogenin should be 
performed in to explore the level of MRF occupancy of these promoters in response to 
ectopic expression of MuRF1.  Our preliminary research suggests that the degree of 
myogenic commitment of the myoblast cells may play a large role in the effects of 
MuRF1. Furthermore, MyoD1 and myogenin have recently been shown to transiently and 
sequentially bind the promoters of other muscle-specific genes,5 suggesting that further 
work should including exploration of this possible regulation its potential contribution to 
cellular differentiation. Furthermore, MRF occupancy of the MuRF1 and MAFbx 
promoters should be evaluated in response to ectopic expression of MuRF1 mutants, as 
well as siRNA knockdown of MuRF1 in cells of varying stages of myogenic 
  
49 | P a g e  
 
commitment. Finally, because skeletal muscle atrophy is a complex process and is 
regulated on many levels, future work should extend beyond the exploration of the 
transcriptional regulation of atrogenes by MuRF1. The analysis of the regulation of 
MuRF1 on a post-transcriptional level would also likely yield important information 
regarding the pathways of muscle plasticity. 
 
Implications of this research 
 This research has allowed for a better understanding of the role that MuRF1 plays 
in the regulation of muscle atrophy. A role of MuRF1 in the modulation of known muscle 
regulatory factors suggests that MuRF1 plays a more global role in muscle dynamics than 
has been previously thought.  A better understanding of the regulation of MuRF1 has 
added crucial pieces to the puzzle of MuRF1’s potential role in muscle metabolic control 
mechanisms. There are also numerous aspects of interest to the clinician as well as to the 
academic researcher, considering that MuRF1 has been implicated in numerous medical 
pathologies. In addition to the well-documented effects during denervation and cachexia, 
MuRF1 has also been recently implicated in muscle wasting associated with acute lung 
injury.38 A better understanding of the regulation of MuRF1, and the regulation of other 
muscle specific genes by MuRF1, is therefore of high interest. 
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Chapter 3: Post-Transcriptional Regulation of MuRF1 and MAFbx 
  
Overview 
 A continuation of the research described in this thesis will involve exploration of 
the regulation of MuRF1 and MAFbx expression at additional genetic levels, namely at 
the post-transcriptional level. Unlike the transcriptional regulation that directly activates 
or represses gene promoters, post-transcriptional regulation often occurs after the DNA 
has been transcribed by RNA Pol II into mRNA, but before the RNA has been translated 
into a protein. This process is often mediated by microRNAs (miRNAs), which are 
frequently localized to the untranslated region of mRNA at the 3’ end of the transcript 
(3’UTR).39 Future work in this area will include an investigation into the effect of 
extracellular signals such as Insulin-like Growth Factor-1 (IGF-1) and Transforming 
Growth Factor-β (TGF-β) on the post-transcriptional regulation of MuRF1 and MAFbx 
via miRNA signaling, since these pathways have been implicated in both microRNA 
regulation and muscle tissue dynamics.40, 41  
 
MuRF1 and MAFbx Have Long 3’ UTRs 
 Both MuRF1 and MAFbx have recently been revealed to have long and highly 
conserved 3’UTRs.  Because the majority of microRNA-mediated post-transcriptional 
regulation occurs at the 3’ region of target mRNA molecules, MuRF1 and MAFbx are 
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below in Figure 24.  
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Figure 25. MuRF1 3' UTR with potential binding sites for known miRNAs
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processes of muscle myoblast differentiation by targeting muscle-specific transcription 
factors such as myogenin and MyoD1 activate genes that induce myoblasts to retreat 
from the cell cycle and ultimately fuse into multi-nucleated myotubes.51  Additionally, 
TGF-β, a known inducer of skeletal muscle atrophy, and IGF-1, a known inducer of 
muscle hypertrophy, both have been shown to affect miRNA expression in skeletal 
muscle.40 Consequently, the role of TGF-β and IGF-1 in miRNA-mediated regulation of 
MuRF1 and MAFbx is a potential avenue of continued exploration in our lab. 
 
IGF-1 and TGF-β Signaling Pathways Regulate Skeletal Muscle Dynamics 
 IGF-1 and TGF-β play important regulatory roles in skeletal muscle hypertrophy, 
atrophy and fibrosis. Furthermore, these growth factors have been shown to impose their 
regulatory effects of muscle-specific gene expression at the post-transcriptional and 
transcriptional levels. For example, Insulin-like growth factor-1 (IGF-1) has been shown 
to induce muscle hypertrophy via the PI3K-Akt-FoxoO pathway leading to decreased 
MuRF1 and MAFbx expression (Figure 28).52  
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TGF-β1 is a well characterized cytokine that promotes the proliferation of fibroblast 
cells, causes fibrosis and inflammation, and is associated with many diseases of skeletal 
muscle.56-58 TGF-β1 also regulates microRNAs that influence skeletal muscle 
differentiation.59  Because TGF-β1 has been implicated in skeletal muscle wasting and 
fibrosis, this research also currently involves the exploration of the miRNA-mediated 
mechanism by which it may affect MuRF1 and MAFbx expression. 
 Interestingly, MAFbx expression levels and muscle protein ubiquitination have 
been demonstrated to increase quickly following TGF-β1 administration, but the 
molecular mechanisms behind the TGF-β1-mediated effects on MAFbx expression are 
not yet fully understood.60, 61 TGF-β1 has also been previously shown to alter muscle 
plasticity via modulation of miR-29, and recently it has been determined that this effect is 
mediated, at least in part, by Smad3 inhibition of MyoD1 binding to the miR-29 
promoter.62 Future research will focus closely on the role of TGF-β1 in the post-
transcriptional regulation of MuRF1 and MAFbx.  
 Finally, IGF-1 has also been shown to block upregulation of MuRF1 and MAFbx, 
in part, through the inhibition of myostatin.63 Myostatin, a member of the TGF-β 
superfamily of genes, phosphorylates and thus activates Smad3, which then regulate 
downstream genes, including MuRF1 and MAFbx.63 The mediation of Smad3 via TGF-
β1 and IGF-1 on MuRF1 and MAFbx expression has beeen explored further in our lab, 
with a focus on the role of miRNAs in this process.  
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Materials and Methods 
 
Cloning of the 3’UTRs of MuRF1 and MAFbx 
 The MuRF1 and MAFbx 3’UTRs were analyzed using the Ensembl database 
(www.ensembl.org). The following primers were designed to amplify ~750 bp of the 
MuRF1 3’UTR and ~1300 bp of the MAFbx UTR: 
MuRF1 FWD:  5’-GC-GAGCTC-AGA AGG AGA TGA GTG AGA CAC GC-3’ 
MuRF1 REV: 5’-GC-AAGCTT-GAG GCA GAG TCT CTC TAT GTA GC-3’ 
MAFbx FWD: 5’-GC-GAGCTC-AT AAT CCC AGC ACA CGA ACA CAC TTC AG-
3’ 
MAFbx REV: 5’-GC-AAGCCT -GTT TGC CAA GAG CAT GCA TAG TGG C-3’ 
 These primers were used in an RT-PCR reaction that consisted of PCR buffer, 
dNTP mixture, 1.5 mM MgCl2, forward and reverse primers, 2.0 µL of RT-reaction, and 
Taq polymerase diluted in nuclease-free water. The cycling conditions were 94°C for 2 
min, followed by 30 cycles of 94°C for 45 sec, 55°C for 1 min, and 72°C for 1.5 minutes, 
a final extension  at 72° for 10 min and then held at 10°C until the reactions were 
removed from the thermocycler. Following PCR, the products were electrophoresed on a 
0.7% agarose gel, purified via a commercial purification protocol (Qiagen, Valencia, 
CA,) and cloned into the pMIR-Report luciferase reporter plasmid (Promega, Madison, 
WI). 
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Construction of 3'UTR-SEAP-Reporter Plasmids 
 Pilot transfection experiments were performed in C2C12 myoblast cells with little 
luciferase activity recorded, so an alternative approach was designed. The 1500 bp 
sequence of secreted alkaline phosphatase cDNA from the pSEAP2-Basic plasmid was 
amplified by PCR and cloned into the pMIR-Report reporter plasmid, lacking the 
luciferase coding region. Briefly, the 1500 bp sequence of the pSEAP2-Basic plasmid 
corresponding to the secretion of alkaline phosphatase was amplified via PCR using 
primers containing restriction enzyme sites for Bgl II in the forward primer and SpeI in 
the reverse primer. The PCR product was then run on a 0.7% gel and purified as 
previously described. The previously-designed pmir-Report plasmids with the MuRF1 
and MAFbx 3’UTRs were digested with Bam HI and Spe I in order to remove the 
luciferase cDNA from the pMIR-Report plasmid. The 1500 bp SEAP fragment was then 
ligated into the linearized MuRF1-3’UTR-pMIR-Report and the MAFbx-3’UTR-pMIR-
Report plasmids lacking the luciferase gene. This effectively formed two original 
plasmids with either the MuRF1 3’UTR or the MAFbx 3’UTR fused to the SEAP gene, 
(MuRF1-SEAP-Report and MAFbx-SEAP-Report, respectively) which are well suited 
for analysis in C2C12 cells.  
 
SEAP Reporter Assays 
 The activities of the newly designed MuRF1-SEAP-Report and MAFbx-SEAP-
Report plasmids were preliminarily tested in mouse myoblast cells. The MuRF1-SEAP-
Report plasmid and the MAFbx-SEAP-Report plasmid was transfected into C2C12 cells 
as described previously. Following a 24 hr incubation at 37°C at 6% CO2, the C2C12 cells 
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were then treated with either 100 pM TGF-β1, 100 ng/ml IGF-1. 1 µM Dexamethasone, 
or a control solution containing only DMEM media. The levels of secreted alkaline 
phosphatase and corresponding plasmid activities were measured at 24 hr intervals using 
a commercial SEAP protocol as described previously in Chapter 2.  
 
siRNA Knockdown 
 siRNA knockdown of Smad3 was performed to further illustrate the role this gene 
plays in the atrophy process. This was accomplished through the use of the pSuper-
siRNA System (OligoEngine), which uses a mammalian expression vector that allows for 
the transcription of short RNA transcripts such as siRNAs. 
 Oligonucleotide sequences were designed to correspond exactly to identified 
nucleotide sequences identified in the mRNA transcript of Smad3. Two unique sequences 
for targeting Smad3 were designed, phosphate end-labeled with T4 Polynucleotide 
Kinase, annealed, cloned into the pSuper plasmid and sequenced to confirm lack of 
mutations. The sequences used were: 
Smad3 Set1  
 
5’ GATCCCC ACT TTC TAC TGC CAC TTG G TTCAAGAGA C CAA GTG GCA GTA GAA AGT TTTT TC       3’ 
3’     GGG TGA AAG ATG ACG GTG AAC C AAGTTCTCT G GTT CAC CGT CAT CTT TCA AAAA AGAGCT   5’ 
 
Smad3 Set2  
5’ GATCCCC GTT CTC CAG AGT TAA AAG C TTCAAGAGA G CTT TTA ACT CTG GAG AAC TTTT TC     3’                    
3’     GGG CAA GAG GTC TCA ATT TTC G AAGTTCTCT C GAA AAT TGA GAC CTC TTG AAAA AGAGCT 5’ 
 
The resulting pSuper plasmids were transfected with the SEAP-MAFbx-Report plasmid 
or the SEAP-MuRF1-Report plasmid into C2C12 cells as described previously. A pSuper-
null plasmid, similarly designed but containing no inhibitory sequences, was used as a 
  
60 | P a g e  
 
negative control. The effects of Smad3 knockdown on the activity of the SEAP-MAFbx-
Report and SEAP-MuRF1-Report plasmids were then analyzed using a commercial 
SEAP protocol as previously described. 
 
 
Preliminary Results 
 As seen below in Figure 29, the MAFbx-SEAP-Report and the MuRF1-SEAP-
Report reporter constructs were successfully engineered and both showed quantifiable 
expression levels following transfection into C2C12 cells. The activity of the constructed 
SEAP-Report plasmids containing either the MuRF1 3’UTR or MAFbx 3’UTR showed a 
marked increase in activity at 72 hrs when compared to the control SEAP-Report-null 
plasmid after treatment with TGF-β1, while IGF-1 had no effect on reporter activity.  
 
 
Figure 29.   The MAFbx-SEAP-Report and MuRF1-SEAP-Report plasmids show an increase in expression in cells 
treated with TGF-β1. C2C2 myoblasts were transfected with the MAFbx-SEAP-Report plasmid, the MuRF1-SEAP-
Report plasmid, or a control plasmid consisting of only the empty SEAP-Report plasmid, and a β-galactosidase 
expression plasmid. The cells were treated with either TGF-β1, IGF-1, or DMEM as a negative control. The myoblasts 
were maintained in standard culture media. Samples of media were taken at 72 hrs and measured for SEAP activity. 
The samples were normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each 
condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean. 
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Furthermore, since dexamethasone is a synthetic glucocorticoid that is known to induce 
muscle atrophy, the activities of the MuRF1 and MAFbx 3’-UTR reporter  constructs 
were  analyzed in cells transfected with the glucocorticoid receptor and treated with 
dexamethasone. The data revealed no significant change in activity of the SEAP-null 
plasmid when treated with dexamethasone, however there was a marked increase in 
activity of both the SEAP-Report-MuRF1-3'UTR plasmid or the SEAP-Report-MAFbx-
3'UTR after treatment with dexamethasone (Figure 30).  
 
Figure 30. The MAFbx-SEAP-Report and MuRF1-SEAP-Report plasmids show increased expression when treated 
with Dexamethasone. C2C12 myoblasts were transfected with the MAFbx-SEAP-Report reporter, the MuRF1-SEAP-
Report reporter, or a control plasmid consisting of only the empty SEAP-Report plasmid, and a β-galactosidase 
expression plasmid. The cells were treated with either dexamethasone or DMEM as a negative control. The myoblasts 
were maintained in standard culture media. Samples of media were taken at 72 hrs and measured for SEAP activity. 
The samples were normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each 
condition was done in triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean. 
 
Finally, since Smad3 has been linked to several miRNA-mediated mechanisms of 
regulation, preliminary work has also involved investigating the effects of Smad3 
knockdown on MuRF1 and MAFbx 3'UTR reporter plasmid activity. To test the role of 
Smad3 in MAFbx expression, activity of the MAFbx-SEAP-Report and MuRF1-SEAP-
Report plasmids were compared to that of an empty control SEAP-Report plasmid with 
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no UTR, under conditions of Smad3 knockdown. Smad3 knockdown was accomplished 
by using either the Smad3-pSuper-siRNA expression plasmid or a control pSuper 
plasmid lacking an siRNA insert. The empty SEAP-Report-null plasmid showed no 
significant differences in activity in normal cells compared to Smad3-knockdown cells, 
while the MAFbx-3’UTR-SEAP-Report and MuRF1-3'UTR-SEAP-Report reporter 
construct showed a significant increase in activity in Smad3 knockdown cells compared 
to normal cells (Figure 31).  
 
Figure 31. The MuRF1-SEAP-Report and MAFbx-SEAP-Report plasmids show an increase in expression in Smad3 
knockdown cells. C2C12 myoblasts were transfected with a reporter construct consisting of the MAFbx-SEAP-Report 
plasmid, MuRF1-SEAP-Report plasmid or a negative control plasmid consisting of only the empty SEAP-Report 
plasmid, and a β-galactosidase expression plasmid. The cells had previously been  transfected with either pSuper-
Smad3 siRNA, or an empty pSuper expression plasmid. The myoblasts were maintained in standard culture media. 
Samples of media were taken at 72 hrs and measured for SEAP activity. The samples were normalized to β-
galactosidase activity to correct for variation in transfection efficiency. Each condition was done in triplicate and the 
error bars represent standard deviation (-/+ S.D.) of the mean. 
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Future Work: 
 In light of the above preliminary results, future work will involve continued 
exploration of the post-transcriptional regulation of MuRF1 and MAFbx with respect to 
Smad3-mediated miRNA activity. A bioinformatics approach was undertaken to further 
characterize the potential contribution of miRNA in the regulation of MuRF1 and 
MAFbx. The TargetScan database (www.TargetScan.org) was used to identify putative 
binding sites for miRNAs in the 3’UTRs of MuRF1 and MAFbx. miR-23 and mir-144 
were identified as having binding sites present in the 3'UTRs of both MuRF1 and 
MAFbx, suggesting possible common patterns of regulation by these miRNAs. mir-23 
has already been shown to play a role in muscle development, while miR-144 has 
recently been shown to be differentially expressed in aging muscle.64, 65 Thus, future work 
on this project should focus on these miRNAs. 
 Reporter assays using the MuRF1-3'UTR-SEAP-Report or MAFbx-3'UTR-
SEAP-Report plasmids should be performed with the simultaneous overexpression of 
miRNA-23 and/or miRNA-144 to determine if these microRNAs can alter the expression 
of the MuRF1 and MAFbx 3’-UTR reporter plasmids. Additionally, the introduction of 
anti-miRNA locked nucleic acids (LNAs) should be used to reverse these miRNA effects. 
LNAs are nucleic acid analogs in which the ribose ring is locked with a methylene bridge 
connecting the 2'-oxygen atom with the 4'-carbon within the ring. These LNAs bind to, 
and effectively inhibit, complementary microRNAs. The combination of experiments 
involving the overexpression of specific miRNAs with experiments involving specific 
miRNA inhibition, will allow us to determine with confidence that these microRNAs 
bind to the UTRs of MuRF1 and MAFbx.  
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 Finally, in order to further examine post-transcriptional regulation of MuRF1 and 
MAFbx, this project will eventually compare levels of MuRF1 and MAFbx protein 
production following deletion of the 3’UTRs of these genes. If the levels of protein 
produced differ following deletion of the 3’UTR, then a post-transcriptional mechanism 
of regulation may be implicated. In order to address these questions, the cDNA molecules 
lacking the 3'UTRs of MuRF1 and MAFbx have been cloned. These genes have been 
tagged with myc, which is polypeptide protein tag, and cloned into expression plasmids. 
Future work will also involve cloning the MuRF1 and MAFbx cDNA with their 3'UTRs, 
tagging them with myc, and inserting them into an expression plasmid. These plasmids 
containing myc-tagged MuRF1 and MAFbx with or without their 3'UTRs will then be 
transfected into C2C12 cells that will be subsequently treated with or without TGF-β1, 
IGF-1, or Dexamethasone. The cells will then be homogenized and proteins lysates will 
be used for Western Blotting to detect MuRF1 and MAFbx protein levels in order to 
determine in changes in protein production that may result due to changes in miRNA 
expression mediated by growth factor treatments. 
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